Andrew Campbell

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Fred Poordad, Christophe Hézode, Roger Trinh et al. · New England Journal of Medicine · 2014 · 872 citations · Full text

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Mark Sulkowski, Joseph J. Eron, David Wyles et al. · JAMA · 2015 · 305 citations · Full text

Comparison of the Effects of Anticardiolipin Antibodies from Patients with the Antiphospholipid Syndrome and with Syphilis on Platelet Activation and Aggregation

Andrew Campbell, Silvia S. Pierangeli, Samuel R. Wellhausen et al. · Thrombosis and Haemostasis · 1995 · 131 citations

Immunology, Pathology, Anticardiolipin Antibodies +18

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

Preethi Krishnan, Jill Beyer, Neeta Mistry et al. · Antimicrobial Agents and Chemotherapy · 2014 · 130 citations · Full text

Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A

David A. DeGoey, John T. Randolph, Dachun Liu et al. · Journal of Medicinal Chemistry · 2014 · 126 citations

Excellent Potency, Medicinal Chemistry, Hcv Ns5a +11